Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRICERATOPS: PPF3 in Autism Spectrum Disorder
NCT07893964Phase 2Recruiting
- Sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, randomised trial in Autism Spectrum Disorder (ASD) comparing Arm 1 (PPF3) with Arm 2 (Placebo) (2 arms). Primary endpoints: Adverse Events at 16 weeks and Clinical Global Impression-Severity at 16 weeks. Started Oct 2026; status: recruiting.
02
Drugs
PPF3
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07893964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07893964.